mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Molecular Biology
• Metabolic Diseases

Background:

• Global nonalcoholic fatty liver disease (NAFLD) prevalence is increasing, necessitating novel therapeutic strategies.
• The complex pathogenesis of NAFLD requires identification of multiple contributing factors beyond the traditional 'two-hit' hypothesis.
• The mechanistic target of rapamycin (mTOR) pathway is a key regulator of cellular processes relevant to liver health.

Purpose of the Study:

• To comprehensively review the multifaceted roles of mTOR in NAFLD pathogenesis.
• To elucidate how mTOR influences key NAFLD-associated pathways including lipid metabolism, insulin resistance, oxidative stress, and inflammation.
• To explore the connection between mTOR signaling, gut microbiota, epigenetics, and NAFLD development.

Main Methods:

• Literature review and synthesis of existing research on mTOR signaling in NAFLD.
• Analysis of mTOR's regulatory mechanisms on cellular and molecular factors implicated in NAFLD.
• Examination of the interplay between mTOR and upstream signaling pathways (Notch, Hedgehog, Hippo) in NAFLD-associated hepatocellular carcinoma.

Main Results:

• mTOR significantly impacts lipid metabolism via SREBPs, insulin resistance through Foxo1 and Lipin1, and oxidative stress via PIG3, p53, and JNK.
• mTOR signaling is intricately linked to intestinal microbiota (TLRs), autophagy, inflammation, genetic variations, and epigenetic modifications in NAFLD.
• Crosstalk between mTOR and Notch, Hedgehog, and Hippo pathways influences the progression of NAFLD to hepatocellular carcinoma.

Conclusions:

• mTOR acts as a central regulator in NAFLD pathogenesis, influencing multiple biological processes.
• Understanding mTOR's complex role offers opportunities for developing novel diagnostic markers and targeted therapies for NAFLD.
• Targeting mTOR signaling pathways presents a promising avenue for future NAFLD treatment strategies.